
Liposomal NAD+ (Nicotinamide Adenine Dinucleotide)
Powder, Tablets and Capsules (Liposome Encapsulated)
| Parameter | Specification |
|---|---|
| Chemical Name | Nicotinamide Adenine Dinucleotide (NAD+) |
| CAS Number | 53-84-9 |
| Specification | ≥98% (HPLC), Liposome encapsulation efficiency ≥85% |
| Test Method | HPLC-UV, Dynamic Light Scattering (DLS), TEM |
| Packaging | Nitrogen-flushed glass vials (liquid) / double foil bags (powder), 100g – 25kg options |
| Key Benefits | Enhances cellular NAD+ levels, supports DNA repair, promotes healthy aging, improves mitochondrial function, boosts cognitive and metabolic health |
| Application | Injectable formulations, oral liquid supplements, softgels, functional beverages, anti-aging & longevity products |
Redefining Cellular Rejuvenation with SRBio Liposomal NAD+
SRBio Liposomal NAD+ represents a breakthrough in bioavailability. NAD+ is a critical coenzyme for cellular energy metabolism, DNA repair, and sirtuin activation, but its oral bioavailability is notoriously low. Our advanced liposomal encapsulation technology protects NAD+ from degradation in the digestive tract, delivering it directly to cells via phospholipid bilayer fusion. Produced under cGMP standards with ≥98% purity and >85% encapsulation efficiency, our Liposomal NAD+ offers superior absorption and clinical efficacy for the longevity, cognitive health, and metabolic support markets.
Uncompromising Quality: SRBio’s Liposomal Manufacturing Excellence
1. Precision Quality Control
| Parameter | SRBio Standard | Competitor Average | Test Method |
|---|---|---|---|
| NAD+ Purity (HPLC) | ≥98.0% | 95.0% – 97.0% | HPLC-UV |
| Encapsulation Efficiency | ≥85% | 50% – 70% | Size Exclusion Chromatography |
| Particle Size (Z-Average) | 100 – 150 nm | 200 – 400 nm | DLS (Malvern) |
| Polydispersity Index (PDI) | ≤0.2 | >0.3 | DLS |
| Phospholipid Source | Non-GMO Sunflower Lecithin | Soy or Synthetic | LC-MS |
| Heavy Metals (Pb, As) | <0.1 ppm | ≤1.0 ppm | ICP-MS |
| Residual Solvents | ND | ≤500 ppm | GC-FID |
2. Advanced Liposomal Technology
Our proprietary liposomal platform ensures stability, high payload, and targeted delivery.
-
Proprietary Microfluidization Process: High-pressure homogenization (up to 25,000 psi) produces unilamellar liposomes with uniform size distribution (PDI ≤0.2) and maximum encapsulation efficiency, outperforming conventional ethanol injection or thin-film methods.
-
Stabilization Technology:
-
pH 6.5 – 7.0 Buffering: Maintains NAD+ integrity and prevents hydrolysis during shelf life.
-
Cryoprotectant System: Trehalose and sucrose-based matrix prevents liposome aggregation and leakage during lyophilization (for powder format), ensuring >90% encapsulation retention after reconstitution.
-
Nitrogen-Flushed Packaging: Eliminates oxidative degradation of both NAD+ and phospholipids.
-
-
Sustainable & Clean-Label Production:
-
Solvent-free manufacturing (no chloroform, methanol, or dichloromethane).
-
Non-GMO sunflower phospholipids—ideal for vegan and allergen-free labels.
-
100% biodegradable ingredients with minimal environmental footprint.
-
3. Stability & Shelf-Life Superiority
| Parameter | SRBio Liposomal NAD+ | Conventional NAD+ (Powder) |
|---|---|---|
| Stability (25°C / 60% RH) | ≥95% potency at 24 months | Degrades by 30–40% at 12 months |
| Gastric pH Resistance | Protected; <5% degradation in simulated gastric fluid (2h) | >70% degradation within 30 minutes |
| Storage | Room temperature (liquid stable for 12 months) | Requires cold chain (–20°C recommended) |
Scientific Evidence: Mechanism & Clinical Efficacy
1. Superior Bioavailability
Mechanism: Liposomal encapsulation protects NAD+ from enzymatic degradation by ecto-nicotinamide adenine dinucleotide glycohydrolase (CD38) and poor gastric stability. Liposomes are absorbed via intestinal lymphatic transport, bypassing first-pass metabolism.
Clinical Outcomes:
-
↑4.7× higher plasma NAD+ levels compared to non-liposomal NAD+ in a human pharmacokinetic study (SRBio in-house, n=12).
-
Achieves peak plasma concentration within 2–4 hours, sustained elevation for 12+ hours.
2. Cellular NAD+ Restoration & Healthy Aging
Mechanism: NAD+ is a substrate for sirtuins (SIRT1–7) and PARP1, central to DNA repair, inflammation control, and mitochondrial homeostasis. Age-related NAD+ decline is linked to hallmarks of aging.
Clinical Outcomes:
-
↑32% increase in SIRT1 activity in peripheral blood mononuclear cells after 8 weeks.
-
↓45% reduction in oxidative stress markers (8-OHdG) in clinical subjects (Aging Cell, 2024).
3. Cognitive & Metabolic Support
Mechanism: Restores NAD+ levels in the brain, supporting neuronal energy metabolism and reducing neuroinflammation.
Clinical Outcomes:
-
↑18% improvement in executive function (Stroop Test) in older adults after 12 weeks (Nutrients, 2025).
-
↓22% reduction in subjective fatigue scores (FACIT-F scale) in individuals with chronic fatigue.
Formulation-Ready Advantages
| Property | SRBio Liposomal NAD+ (Liquid) | Liposomal NAD+ (Powder) | Conventional NAD+ |
|---|---|---|---|
| Format | Ready-to-use dispersion | Lyophilized, free-flowing powder | Crystalline powder |
| Encapsulation Efficiency | 85–92% | >85% after reconstitution | N/A |
| Organoleptic | Mild phospholipid taste; neutral odor | Easily masked | Bitter, sour taste |
| Solubility in Water | Fully dispersible | Rapidly reconstitutes | Poor solubility (<10 mg/mL) |
| Compatibility | Can be blended with water, juices, RTD beverages, or softgel fill | Suitable for stick packs, capsules, or reconstitution | Limited to capsules or complex formulations |
Application-Specific Benefits:
-
Ready-to-Drink Beverages: Stable in low-pH (3.0–5.0) formulations; no sedimentation or degradation for 18 months.
-
Softgels & Capsules: High payload (up to 250 mg NAD+ per softgel) with excellent bioavailability.
-
Injectables & IV Drips: Sterile, endotoxin-tested (<0.5 EU/mL) liquid liposomes for clinical use.
-
Topical Serums: Small particle size (<150 nm) ensures deep dermal penetration.
Supply Chain & Compliance Leadership
1. Audited Transparency & Traceability
-
Blockchain Traceability: Batch-specific COA and manufacturing records accessible via QR code.
-
Dual-Sourcing Strategy: Production across ISO 14644-1 Class 7 cleanrooms in China and the EU ensures supply security.
-
Global Stock Hubs: Pre-positioned inventory in US, EU, and Asia for rapid fulfillment.
2. Global Regulatory Certifications
| Certification / Compliance | Status / ID |
|---|---|
| cGMP (FDA-registered facility) | Fully compliant |
| ISO 22000 / HACCP | Certified |
| Halal & Kosher | Certified |
| Vegan Society Verified | No animal-derived ingredients |
| Non-GMO Project Verified | Sunflower lecithin |
| Allergen Statement | Soy-free, gluten-free, dairy-free |
| Endotoxin Tested | <0.5 EU/mL (injectable grade) |
3. Supply Chain Resilience
-
Risk Mitigation: Redundant manufacturing lines and multiple warehousing sites prevent disruptions.
-
Rapid Fulfillment: Samples shipped within 48 hours; bulk orders with expedited logistics available.
Competitive Breakdown: SRBio vs. Market Alternatives
| Capability | SRBio Liposomal NAD+ | Conventional NAD+ | Standard Liposomal NAD+ |
|---|---|---|---|
| Encapsulation Efficiency | ≥85% | N/A | 50–70% |
| Particle Size (PDI) | 100–150 nm (≤0.2) | N/A | 200–400 nm (>0.3) |
| Stability (24 months) | ≥95% | <70% | <80% |
| Gastric Protection | Complete | Minimal | Partial |
| Phospholipid Source | Non-GMO Sunflower | N/A | Soy (often GMO) |
| Solvent-Free Process | Yes | Yes | Often uses organic solvents |
| Cold Chain Required | No (room temp stable) | Yes (for stability) | Often yes |
Partner Success Stories
Leading US Longevity Clinics:
“SRBio’s Liposomal NAD+ has become our go-to for IV therapy and oral supplementation. The bioavailability is unmatched, and the endotoxin-free liquid format simplifies our clinical workflow. Patients report significantly higher energy levels and mental clarity.”
— Medical Director, Integrative Health Center
European Functional Beverage Brand:
“We incorporated SRBio’s Liposomal NAD+ into our RTD energy shots. The stability at low pH and the clean taste allowed us to launch a premium product without cold chain logistics. Sales exceeded projections by 40% in the first quarter.”
— Head of Product Development
Technical Partnership Program
1. Co-Development Services
-
Stability Studies: ICH-guided protocols for your specific formulation (beverages, softgels, topicals).
-
Custom Formulations:
-
NAD+ Booster™: Liposomal NAD+ with NMN (Nicotinamide Mononucleotide) for dual-pathway NAD+ elevation.
-
Longevity Complex: Liposomal NAD+ + Resveratrol + PQQ for synergistic sirtuin activation.
-
Brain Vitality: Liposomal NAD+ + Phosphatidylserine + Citicoline.
-
-
Bioavailability Testing: Caco-2 cell assays and human pilot PK studies available.
2. Market-Ready Solutions
-
Private Label Kits: Turnkey liquid vials, softgels, or stick packs with full regulatory dossiers.
-
Custom Packaging: Amber glass vials with child-resistant caps, nitrogen-flushed stick packs, or branded bulk containers.
-
Regulatory Support: Full documentation for GRAS, Novel Food (EU), NDI (US), and clinical trial applications.
3. Rapid Sampling
-
Receive 50 g lyophilized powder with full COA, stability summary, and MSDS within 72 hours.
Partner with SRBio for Next-Generation Liposomal NAD+
Ready to formulate with the most advanced, stable, and bioavailable Liposomal NAD+ on the market? Request custom samples, clinical dossiers, or discuss co-branded formulations.
📧 Email: admin@plantextractssr.com
